About Pharmacology 2018

2nd International Conference & Expo on Pharmacology & Regulatory Affairs

Cenetri Publishing Group reunite all the participants around the world to join the "2nd International Conference and Expo on Pharmacology & Regulatory Affairs" with the theme of "Cutting Edge Research Works in Pharmacy & Drug Development" scheduled at Berlin, Germany. It is a broad-based topic founded on two key tenets: To explore the most exciting researches with respect to the subjects on Pharmaceutical Regulatory Affairs: Secondly, to provide a rapid turn-around time possible to research, teaching and reference purposes.

This conference will provide the finest platform where you can deliberate the prominence of pharmacology & regulatory affairs that covers research on the toxicological an pharmacological effects of environmental contaminants, pharmacologic concerns on both experimental and clinical levels, clinical toxicology, pharmacokinetics, pharmacodynamics, drug interactions, collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products.

Importance of Pharmacology & Regulatory Affairs

Pharmacology is the branch of medicine concerned with the uses, effects and modes of action of drugs. It studies how different chemicals affect biological systems, and incorporates knowledge and skills from a number of basic science disciplines including physiology, biochemistry, and cellular and molecular biology. The Regulatory Affairs department is an important part of the organizational structure of pharmaceutical companies. Internally it liaises at the interphase of drug development, manufacturing, marketing and clinical research. Externally it is the key interface between the company and the regulatory authorities. It is actively involved in every stage of development of a new medicine and in the post-marketing activities with authorized medicinal products.

Scope of Pharmacology & Regulatory Affairs

The scope of pharmacology is rapidly expanding and provides the rational basis for the therapeutic use of the drug. The success of regulatory strategy is less dependent on the regulations than on how they are interpreted, applied, and communicated within companies and to outside constituents. Regulatory Affairs plays a crucial role in the pharmaceutical industry and is involved in all stages of drug development and also after drug approval and marketing as the drug development process is a lengthy, complex and extremely costly albeit necessary process. Pharmacology has a wide scope, and derives from various other disciplines like physiology, microbiology, pathology, biochemistry and various clinical specialties.

The major challenges of the regulatory bodies are:

  • To promote public health and protect the public from harmful and dubious drugs
  • To establish proper legalization covering all products with a medicinal claim and all relevant pharmaceutical activities, whether carried out by the public or the private sector.
  • To increase worldwide regulatory growth to ensure safety of people.
  • To understand the process of drug intake, absorption, distribution, metabolism and elimination.

Scientific Sessions

  • Advances in Pharmacology
  • Clinical Pharmacology
  • Pharmacogenomics
  • Pharmacokinetics
  • Pharmacoepidemiology
  • Pharmacotherapy and Posology
  • Neuropharmacology
  • Psychopharmacology
  • Pediatrics Pharmacology
  • Toxicology
  • Theoretical Pharmacology
  • Behavioral Pharmacology
  • Environmental Pharmacology
  • Drug Delivery and Formulation
  • Drug Design and Discovery
  • Bioequivalence and Bioavailability
  • Adverse Drug Reaction and Treatment
  • Clinical research and Drug Legislation
  • Pharmacovigilance and Drug safety
  • Pharmaceuticals and Personal Care Products

Societies and associations of Pharmacology & Regulatory Affairs

  • Safety Pharmacology Society
  • American Society for Pharmacology
  • Royal Pharmaceutical Society
  • Canadian Society of Pharmacology and Therapeutics
  • Association for Ocular Pharmacology
  • Regulatory Affairs Professionals Society
  • Canadian Association of Professionals in Regulatory Affairs
  • The European Association for Clinical Pharmacology and Therapeutics (EACPT)
  • Rocky Mountain Regulatory Affairs Society
  • Belgian Regulatory Affairs Society
  • Korean Society of Pharmacology
  • Malaysian Society of Pharmacology and Physiology (MSPP)
  • Pharmacological Society of Taiwan
  • Japanese Pharmacological Society
  • Pharmacy and Drug Control
  • The Federation of European Pharmacological Societies

Why to Attend ?

  • This conference provides the chance to Meet and network 100+ industry leaders and peers, with co-located events under Pharmacology and gain critical advises from industrial experts on the related regulation matters.
  • To grasp and gain the quality information in terms of breadth and depth of key topics on production registration, submission, pharmacovigilance, clinical regulatory requirements and other topics with respect to the scientific sessions.
  • To take the opportunity of exchanging, circulation and gaining the knowledge and ideas for the future prospects.

Target Audience

  • Academicians
  • Researchers
  • Healthcare Technology Providers
  • Healthcare Professionals
  • Pharma Industrialists
  • Pharmacists
  • Medical Directors
  • Principal Investigators
  • Methodologists and other Regulatory professionals along with Academicians
  • Graduates and Post graduates in Industrial Pharmacy
  • Medical Devices Manufacturing Companies, CRO
  • Data Management Companies.
  • Pharmaceutical legislators and regulators
  • Toxicology Testing Companies & Organizations

Market report

The global $1.12 trillion market in 2022, will rise at a faster clip during 2016-2020, then slow down a bit as major patent expiration take hold. It is expected that the global market declined by 1.0% in 2015, but will grow by 4.8% this year. Prescription sales excluding generics will rise 4.4% this year, and expected to reach $1.006 trillion in 2022. Generics sales will increase from $73 billion in 2015 to $115 billion in 2022, and constitute 10.2% of prescription sales at that point only 0.3 percentage points more than it is now.


  • Reason 1: Drug Companies Can Charge Whatever Price They Want.
  • Reason 2: Insurance Companies Are Also Charging You More.
  • Reason 3: Old Drugs Are Reformulated as Costly 'New' Drugs.
  • Reason 4: Generic Drug Shortages Can Trigger Massive Price Increases.
  • Reason 5: Specialty Drugs Are Costing All of Us.